ImmutriX Therapeutics, Inc., is a medical technology company located in Rapid City, South Dakota. Incorporated in the State of South Dakota, it is privately funded and currently employs 12 people.
ImmutriX Therapeutics developed an innovative medical device for cleansing whole blood to modulate and sequester molecules from circulation known to be contrary to health. ImmutriX products target and bind molecules (“modifiers”) of interest in a “dialysis-like” procedure to treat a broad range of medical conditions. The Modifiers to be removed are those molecules which cause an undesired immune or pathological response, often referred to as mediators.
ImmutriX is elevating proven science to advanced levels. It is leveraging and adapting multiple high technology platforms and creating therapeutic applications for rapid-response treatments to remove toxins, poisons, and biological modifiers.
ImmutriX’s blood-cleansing process uses proprietary materials contained in an extracorporeal device to modulate blood components to provoke a desired response of eradicating or stabilizing a specific disease condition.
An estimated seventy molecular targets can be removed by this blood-treatment system that is applicable to about fifty medical conditions and diseases.
ImmutriX’s research shows the body’s natural mechanisms can be facilitated by depleting specific mediators from circulation often caused by an inappropriate immune response to a pathogen or toxin. These targets act as inhibitors of normal immune function and are attributable to the pathophysiological cascade that leads to severe conditions, complications, and even death. Mediators are present in blood when there is an acute, acute on-chronic, or chronic medical condition.
Inflammatory mediator’s cytokines, chemokines, and immune molecules (antigens and antibodies) are a major factor in exacerbating a wide range of medical conditions. These substances cannot be easily eliminated by dialysis-based systems because of their molecular structure and tiny size, but they can be readily eliminated or significantly reduced in the patient’s blood with ImmutriX’s technology. This occurs without depleting necessary blood components such as platelets, albumin, potassium and magnesium.
By interrupting the cascade of events elicited by the cytokine storm, toxin, or other inappropriate immune responses, many patients are expected to recover – or at least slow the progression of their medical condition – when treated with the ImmutriX blood-cleansing treatment system.
